In coronary artery disease (CAD), a potentially reversible factor leading to cardiac death is left ventricular hypertrophy (LVH). While the electrocardiogram (ECG) is a widely available way to diagnose LVH, its sensitivity and specificity has never been assessed in this particular patient group where added ischaemic changes on ECG might complicate things. Furthermore, there are at least 11 different ECG criteria proposed to identify LVH. We sought to determine how many cases of echocardiography (echo) LVH would be missed if all of these different ECG criteria were applied in a group of stable, treated angina patients. A total of 241 consecutive patients with angiographically confirmed CAD were prospectively recruited and 11 ECG criteria were assessed on each subject and compared with the presence or absence of LVH on echo. Individual sensitivity, specificity, positive predictive value and negative predictive value were calculated for each ECG LVH criteria. The prevalence of echo LVH in the entire CAD population was 43%. All the proposed ECG criteria were poor at identifying echo LVH. The Cornell product yielded the highest rate of change value but still missed up to 80% of the echo LVH cases. We conclude that in a group of stable, treated angina patients, ECG is an unreliable method of identifying LVH. As LVH is very common in this patient population, screening by means of echo might be indicated. This will enable intensified efforts to ensure LVH regression, which is associated with reduction in both cardiovascular morbidity and mortality.
Introduction
Left ventricular hypertrophy (LVH) is associated with increased risk of cardiovascular morbidity, all cause mortality and sudden cardiac death. 1 This has been shown to be independent of conventional cardiovascular risk factors. Recent evidence shows that LVH is an important cause of cardiac death even in patients with overt coronary artery disease (CAD). This is based on two main observations. Firstly, LVH is more prevalent in this patient population than in the general population. In a study carried out in a predominantly black population with established CAD, the prevalence of echocardiography (echo) LVH was as high as 50%. 2 We recently found similar figures, 3 while according to Framingham, the prevalence would be around 30-35% in controls. Secondly, in a comparative study in CAD patients, Liao et al. 4 showed that the independent relative risk of cardiac death conferred by LVH was higher (2.4) and accounted for more deaths than multivessel coronary disease (relative risk ¼ 1.6) or LV systolic dysfunction (relative risk ¼ 2.0). Therefore, it appears that LVH is a strong, if not the strongest, risk factor in CAD. In addition, recent studies have also demonstrated that LVH regression is associated with improved clinical outcome. In the hypertensive population, ECG and echo LVH regression has been associated with a significant reduction in both fatal and non-fatal cardiovascular events. 5, 6 In a recent review, Mancini et al. 7 emphasized, 'We now have the ultimate documentation for both ECG LVH and echo LVH that reversal has an independent prognostic value, independent of therapy and blood pressure'. 7 This view was endorsed again by Schillaci et al. 8 Nevertheless, detection of LVH in CAD remains a challenge. While echo is a reliable method for detecting anatomic LVH, it is less widely available especially in the non US countries and obviously requires technical expertize. Conversely, the 12-lead ECG is universally available, technically easy to perform and highly specific. The major limitation of the ECG in other populations is its low sensitivity in detecting LVH. Previous epidemiology studies have examined the sensitivity and specificity of various ECG criteria in picking up echo LVH in the general population and in hypertensives. 9, 10 Despite the importance of detecting LVH in CAD, the ability of different ECG criteria to detect echo LVH in this specific population has never been addressed. In addition, ischaemic related ST segment changes in CAD might complicate ECG interpretation. Our study aims to answer this question and in this analysis, we used a larger number of ECG criteria (11) than in previous studies. The main aim of our study is to see how many cases of echo LVH would be missed in a prospective cohort of 241 stable, treated angina patients by applying each of these many ECG criteria.
Methods
A total of 351 white patients with the diagnosis of stable angina who had all undergone diagnostic coronary angiography (between 2002 and 2005) were consecutively recruited from the Cardiology Department, Ninewells Hospital, Dundee. The inclusion criteria were a history of ischaemic chest pain and the presence of angiographically proven CAD (greater than 50% reduction in the cross sectional diameter of a major coronary artery). Majority of them had been treated with stable antianginal medication for approximately 1 year ( Table 1 shows the breakdown of antianginal treatment of the entire study population at the time of study) and the majority had no ongoing symptoms of angina pectoris. The exclusion criteria include:
(1) Recent hospital admission with troponin-T 40.01 ng ml À1 in the last year. (2) Valvular, pericardial or congenital heart disease (3) An impaired LV function (characterized by regional wall motion abnormality or LV ejection fractiono45%) on ventriculography or echo.
All subjects attended a single clinic visit and underwent the following: history, past medical history, clinic blood pressure (BP) measurement, electrocardiography, routine blood tests and transthoracic echo. Ethical approval was obtained from the Tayside Committee of Medical Research Ethics and all participating subjects gave written informed consent. Other details of this study are already published, especially data on the relationship between BP and LVH.
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Definition of a normal clinic blood pressure A 'normal' clinic BP was defined as p140/90 mm Hg as previously described in the British Hypertension Society (BHS) IV guidelines. 12 In contrast, the 'target' BP for treating CAD was p130/80 mm Hg.
ECG assessment of LVH Simultaneous 12-lead electrocardiograms were obtained for analysis, calibrated to 20 mm mV À1 and 25 mm s À1 . ECG analysis was performed manually with an ECG image digitizer board, by a second researcher (IT) blinded to patient details and the echo results. Three QRS complexes' per lead were analysed and the mean value used. We applied two ECG criteria for LVH used in the Losartan Intervention for Endpoint Reduction (LIFE) study as well as an additional nine previously reported ECG criteria for LVH, all of which are sufficiently straightforward to be used in routine clinical practice. The ECG criteria are as follows:
(1) Sokolow-Lyon voltage, SV 1 þ (RV 5 or RV 6 ) X38 mm (2) Gender-specific Cornell voltage, SV 3 þ RaVL 420 mm in women, 428 mm in men 
Left ventricular hypertrophy assessment
Patients were studied with two-dimensional guided M-mode echo in standard views. All measurements were made according to the American Society of Echocardiography recommendation at end diastole, taken as the onset of QRS complex. The leadingedge to leading-edge convention was used to measure interventricular septal thickness, LV internal diameter and LV posterior wall thickness. Measurements were made over at least three separate cardiac cycles and the average was taken. LV mass (LVM) was calculated according to the formula of Devereux et al. 13 0.80 (American Society of Echocardiography LVM) þ 0.6 and indexed to body surface area to give an LVM index (LVMI). LVH was defined as LVMI greater than 110 g m À2 in female and greater than 134 g m À2 in male subjects.
14 LVM was also indexed to height 2.7 and LVH was defined as LVMI 447 g m À2.7 in female and 450 g m À2.7 in male subjects. 15 LVMI was not calculated in cases in which either poor image quality or inadequate image alignment prevented accurate M-mode measurements from being made.
Statistics
We calculated the sensitivity, specificity, positive predictive value and negative predictive value for each criterion. Receiver-operator curves were also constructed. We also separately analysed the 11 proposed ECG criteria for LVH in the hypertensive subgroup of the CAD population.
Results
Of the 351 consecutive patients recruited, 29 patients were excluded due to the presence of impaired LV systolic function or valvular heart disease on echo. Of the remaining 322 patients, an LVM was obtainable in 267 patients (83%). Those in whom LVM could not be assessed did not differ significantly in any parameters from those in whom an adequate M-mode measurement was obtained. A further 26 patients were excluded from the remaining 267 patients due to the presence of bundle branch block morphology on ECG (defined as QRS duration 4150 ms). This yielded 241 patients whereby the various ECG LVH criteria were compared with the presence/absence of echo LVH. Table 1 demonstrates the demographics of the patient population. The average duration between patients undergoing diagnostic coronary angiography and clinic attendance for electrocardiography/ echo was 19 months. The reason for this delay was that we wanted stable patients whereby antianginals that might potentially alter LVM were stable for around 1 year. The CAD population consisted of predominantly male patients with a mean age of 64 years; 53% of the patients had a history of hypertension. About 70% of the patients had coronary artery revascularization (CABG/PCI) in the past and majority were on optimal antianginals and secondary prevention therapy during clinic attendance. Table 2 presents the prevalence of echo LVH according to the two criteria used and the sex distribution. Regardless of the method of indexation used, the prevalence of LVH in this patient population was worryingly high (46% when indexed to Tables 3 and 4 demonstrate the sensitivity, specificity, positive predictive value and negative predictive value and the area under the receiveroperator curve for the various ECG criteria in detecting echo LVH. As expected, all ECG criteria showed excellent specificity but very poor sensitivity, resulting in poor rate of change values. Tables 5  and 6 illustrate the same data in the hypertensive CAD subgroup. The same pattern emerges, whereby all the 11 ECG criteria missed detecting majority of the echo LVH cases.
Discussion
There are several important aspects to our study. Firstly, the value of various ECG criteria in detecting echo LVH has never been specifically assessed in a CAD population. This is despite evidence suggesting that angina patients have a higher prevalence of echo LVH than the general population. Secondly, we did a more comprehensive assessment of different ECG criteria than previously published. Our findings suggest that a large proportion of angina patients with echo LVH will be undiagnosed if we were to solely employ ECG as a diagnostic tool. Thirdly, the prevalence of echo LVH is high in our study population and (46% when indexed to body surface area and 73% when indexed to height 2.7 ) and reiterates the potential importance of screening for this condition and finding novel ways to regress LVH especially in 'normotensive LVH'.
ECG LVH has long been regarded as a harbinger of cardiovascular morbidity and mortality. Its association with adverse prognosis has been consistently shown in both the general population and the hypertensive cohort. 16, 17 However, despite its high specificity in detecting LVH, its clinical utility has been limited by its low sensitivity. 9 Various ECG criteria for diagnosing LVH exist. Up to date, the Sokolow-Lyon criterion remains the most widely used criterion as it is easy to employ. In the most recent ESH-ESC guidelines, the Sokolow-Lyon criterion was recommended as part of all routine assessment of subjects with hypertension. 18 In LIFE, the Sokolow-Lyon criterion and the Cornell product were both used as entry criteria for the study. 5 In our study, the Cornell product consistently outperformed the Sokolow-Lyon criteria in identifying echo LVH regardless of the method of indexation used or the presence/absence of hypertension. In fact, the Cornell product yielded the highest rate of change value compared with the other 10 ECG criteria. Okin et al. 19 showed that the simple product of Cornell voltage Â QRS duration significantly improved the identification of LVH. Despite this, employing the Cornell product would still result in a substantial under detection of LVH in our study population (missing out 80% of the LVH cases). In the Framingham Heart Study, factors that were known to reduce the sensitivity of fixed voltage thresholds include obesity and smoking. 9 Not surprisingly, in our CAD population with a mean body mass index of about 30 and a large proportion of patients with a smoking history, majority of the ECG criteria fared poorly in terms of sensitivity. In addition, the LIFE investigators also showed that obese patients tended to have lower Sokolow-Lyon voltages than non-obese patients but had higher Cornell product. 20 The importance of detecting LVH in CAD patients is based on several reasons. Firstly, three previous studies in CAD patients have demonstrated that the relative risk of cardiac death conferred by LVH was 2.14, 2.4 and 2.1 after adjustment for other factors including hypertension and the number of coronary vessels affected. Secondly, there is now strong evidence to suggest that regression of LVM is associated with improved prognosis in hypertensive patients. Therefore, it is conceivable that similar benefit would occur in CAD patients and future studies should specifically address this issue. In a substudy of LIFE, lower LVM during antihypertensive treatment was associated with lower rate of clinical end points independent of BP lowering effects. 21 In a separate study, the lack of decrease or the increase in LVM during antihypertensive treatment was associated with increased risk of cardiovascular events. 22 Thirdly, a hypothetical analysis suggests that identifying and regressing LVH in normotensive patients with angina should be worthwhile and cost-effective. 23 It is worth noting that the mean BP of our study population (136/74 mm Hg) is still not within the target recommendation of the most recent Joint British Society (JBS) 2 guidelines (o130/ 80 mm Hg). 24 In fact, EUROASPIRE shows that many patients with CAD in the real world fail to achieve target BP and this is sometimes called 'therapeutic 25 The value of detecting LVH in high risk population is also important because studies have shown that the knowledge of yet another risk factor i.e. LVH would prompt physicians towards instituting more aggressive secondary prevention treatment. 26 Studies are now being conducted, looking at further ways to regress LVH over and above 'AII withdrawal therapy'. This could mean the achievement of lower than conventional BP targets in those with LVH (for example, systolic BP of 120 mm Hg) or even an individualized BP target level that ensures full LVH regression in that individual. In the 4E study, the addition of an aldosterone blocker to ACE-inhibitor achieved greater reduction in LVM. A third possibility, which has been shown already to regress LVMin normotensive diabetic patients is trientine-a copper chelating agent. 27 In summary, our study demonstrates that using any of ECG criteria proposed to identify LVH in CAD patients is unreliable and would result in a substantial under detection of this condition. The best performing ECG criteria in our study was the Cornell product but this method still missed approximately 80% of the LVH cases. This implies that echo screening for LVH in all CAD patients might be necessary as LVH regression is associated with reduction of both cardiovascular morbidity and mortality. Future studies should address the cost effectiveness of screening for fully regressing echo LVH in CAD patients, especially in the non US countries, whereby the availability of echo is limited and not all CAD patients undergo echo.
What is known about this topic:
K In coronary artery disease, LVH is an important risk factor that leads to increased cardiac death. K The ECG remains a widely used tool in identifying LVH because it is easily available. K However, the sensitivity and specificity of various ECG LVH criteria have never been assessed in this patient population whereby added ischaemic changes might complicate interpretation.
What this study adds: K We analysed 11 different ECG LVH criteria in 241 stable, treated angina patients and correlated them with echocardiographic LVH. K The prevalence of echo LVH in the entire CAD population was 43%. All the proposed ECG criteria were poor at identifying echo LVH. The Cornell product yielded the highest ROC value but still missed up to 80% of the echo LVH cases. K Majority of ECG LVH criteria are poor at identifying LVH in CAD. As this condition is very common in this patient population, screening by means of echocardiography might be indicated
